1. Intrathecal injection of Kv4
Intrathecal injection of Kv4.3 ASO reduces all Kv4 complex components in the L4–L6 DRGs. Rats were intrathecally injected with Kv4.3 ASO twice daily for 3 consecutive days (D1–D3) and killed on day 4 (D4) or D7.
Intrathecal injection of Kv4.3 ASO reduces all Kv4 complex components in the L4–L6 DRGs. Rats were intrathecally injected with Kv4.3 ASO twice daily for 3 consecutive days (D1–D3) and killed on day 4 (D4) or D7. Rats injected with vehicle (V) or LacZ ASO (Z) were used as controls. A, In the L5 DRG of rats treated with Kv4.3 ASO, Kv4.3-, KChIP1-, KChIP2-, and DPP10-IR were greatly reduced on D4 but returned to the normal levels on D7. Scale bar, 40 μm. B–E, Quantitative data of A. C, C7 DRG. L, L5 DRG. F–I, Western blotting was performed using total proteins (F, G) or plasma membrane proteins (H, I) isolated from the bilateral L4–L6 DRGs on D4. Kv4.3 ASO treatment reduces Kv4.3, KChIP1, and DPP10 in both protein preparations. Bands of GAPDH and cadherin were loading controls for total proteins and plasma membrane proteins, respectively. Data are mean ± SD (n = 3). **p < 0.01, compared with vehicle (normalized to 1; Student's t test). ***p < 0.001, compared with vehicle (normalized to 1; Student's t test).
Yen-Ling Kuo et al. J. Neurosci. 2017;37:
©2017 by Society for Neuroscience